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Anaemia among patients with congestive cardiac failure in 
Uganda – its impact on treatment outcomes
Julius Kabbali Kuule, Emmanuel Seremba, Juergen Freers
Congestive cardiac failure (CCF) is a lethal end-stage 
complication of cardiovascular diseases of which the 
causes include hypertension, rheumatic heart disease and 
cardiomyopathies, and has reached epidemic proportions.1 
CCF affects 2% of the world’s population, and its prevalence 
increases with age.2 Cardiovascular diseases are an increasing 
cause of morbidity and mortality, and in 1990 two-thirds of all 
deaths from cardiovascular disease occurred in the developing 
world.1 
The burden of CCF is expected to rise as medical and 
surgical interventions improve the prognosis of the underlying 
cardiac diseases, and as the proportion of elderly people 
increases.3  Epidemiological studies indicate a poor outcome 
with regard to progression and survival, with a mortality rate 
for patients with CCF  being 4 - 8 times that of the general 
population of the same age.2 The 1-year mortality rate for 
mild CCF is about 15%, increasing to 50% for severe disease.4 
Long-term survival of patients with CCF is poor, with only 
25% of men and 38% of women still alive at 5 years.5 Effective 
management depends on knowledge of factors that determine 
morbidity and mortality in this patient subset. Anaemia is a 
common co-morbidity in CCF and has important implications 
for management and outcome. 
In developed countries short-term management outcomes 
include a mean in-hospital mortality rate of 6.4% and an 
average length of stay in hospital of 7.4 days.6 There are limited 
data on long- and short-term outcomes for CCF patients in sub-
Saharan Africa.
Methods
This was a cross-sectional study in which patients admitted 
to the medical wards of Mulago national referral hospital, 
Kampala, Uganda, were recruited. The study was approved by 
the Makerere University College of Health Sciences Research 
and Ethics Committee and the Uganda National Council for 
Science and Technology. Consecutive patients admitted to the 
wards were approached and briefed about the study. Informed 
consent was obtained from participants. Minor children 
(N=10, ages 13 - 17) were recruited after obtaining assent from 
them and consent from their legal guardians. Participants 
were followed up prospectively for 2 weeks to determine 
the outcome of their treatment. Unconscious patients were 
excluded.  
A diagnosis of CCF was made using the Framingham 
criteria and classified according to severity using the New 
York Heart Association (NYHA) grading system. In addition 
to echocardiography and measurement of the haemoglobin 
(Hb) concentration, socio-demographic data and information 
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Background. Anaemia increases morbidity and mortality in 
patients with congestive cardiac failure (CCF). Few studies 
have examined the prevalence of anaemia and its impact 
among patients with CCF in sub-Saharan Africa. We assessed 
the prevalence of anaemia and its influence on treatment 
outcome in patients with CCF attending a large referral 
hospital in Kampala, Uganda. 
Methods. Echocardiography was done and haemoglobin 
levels were determined in 157 patients with CCF admitted to 
Mulago Hospital. The patients were followed up for 2 weeks 
and their treatment outcome was recorded.  
Results. Of the 157 patients, 101 (64.3%) had anaemia (mean 
haemoglobin concentration ≤11.9 g/dl for women and ≤12.9 
g/dl for men) at admission. Increasing age and hypertensive 
heart disease were significantly associated with anaemia 
(odds ratio (OR) 2.92, confidence interval (CI) 1.41 - 6.05, 
p<0.01 and OR 0.31, CI 0.13 - 0.74, p< 0.01, respectively). 
In-hospital mortality at the end of the 2 weeks of treatment 
was 10.2% and was significantly higher among the anaemic 
patients than their non-anaemic counterparts (OR 4.9, CI 1.07 
- 22.35, p<0.03). The mean duration of in-hospital stay was 7.5 
(standard deviation 3.4) days. This did not differ significantly 
between anaemic and non-anaemic patients. 
Conclusion. The prevalence of anaemia among patients with 
CCF attending Mulago Hospital was high. Anaemia in these 
patients was significantly associated with mortality by the 
end of 2 weeks of treatment.  
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on risk factors for cardiac disease (including rheumatic fever, 
cardiomyopathies, previous hospitalisation and cardiac-related 
surgery) were collected by questionnaire. Echocardiography 
was done using a digital Sonoace 9000 Echo Copier (Medison 
Co. Ltd, Serial SA 5500 100 – 120/200 – 00501), while Hb was 
measured on a haemolyser (CELL-DYN 1700 system 1995).
The prevalence of anaemia was calculated as the proportion 
of men and women who had low Hb levels (≤11.9 g/dl for 
women and ≤12.9 g/dl for men). Anaemia was categorised as 
mild (Hb 10 - 11.9 g/dl for women and 10 - 12.9 g/dl for men), 
moderate (Hb 7 - 9.9 g/dl for both genders) or severe (Hb <7 
g/dl). Categorical variables including gender, causation of 
CCF and NYHA class were presented using frequencies and 
percentages and then cross-tabulated against the outcome 
variable (anaemia). Continuous variables such as age, urea, 
creatinine and fractional shortening were compared between 
the anaemic and non-anaemic patients using the independent-
samples t-test for comparison of means. Levine’s test for 
equality of variances and the significance level corresponding 
to the assumption of equal variance was used. The value of 
the t-statistic for the equality of means was used as a measure 
of strength of association. Multivariate logistic regression was 
used to determine strength of association between the presence 
of anaemia and other variables found to be significantly 
associated with anaemia at bivariate analysis.
Results
Patient characteristics 
Of the 157 patients studied, 104 (66.2%) were female. The mean 
age was 45 years (range 13 - 99). 
Underlying causation of CCF 
Rheumatic heart disease (28.2%), dilated cardiomyopathy 
(27.3%), hypertensive heart disease (25.1%) and 
endomyocardiofibrosis (EMF) (14.3%) were the most common 
underlying cardiac diseases, followed by degenerative valvular 
heart disease (1.9%), hypertrophic cardiomyopathy (1.3%) and 
ischaemic heart disease (1.9%), which was presumably due to 
coronary artery disease (Fig. 1). Most patients were admitted in 
severe CCF (NYHA classes III (59.9%) and IV (36.9%)). Only 5 
(3.2%) were admitted in NYHA class II, and no patient was in 
NYHA class I.
Prevalence, severity and type of anaemia, and 
associations (Table I)
Anaemia was highly prevalent, occurring in 64.3% of the 
patients with CCF. The mean Hb was 11.2 g/dl (standard 
deviation (SD) 8.69). The prevalence of anaemia decreased 
along the scale from mild (31.2%) to severe (6.1%). The 
commonest type of anaemia was normocytic normochromic 
(88.2%). 
Having hypertensive heart disease was significantly 
associated with anaemia (odds ratio (OR) 0.31, 95% confidence 
interval (CI) 0.13 - 0.74, p<0.01), as were increasing age (>50 
years) (OR 2.92, CI 1.41 - 6.05, p<0.01) and raised creatinine 
(>133 µmol/l) (OR 0.17, 95% CI 0.08 - 0.37, p<0.01) and urea 
(>17.85 mmol/l)  (OR 0.12, 95% CI 0.05 - 0.31, p<0.01). 
Management outcomes
We examined mortality at the end of 2 weeks of hospitalisation 
and length of in-hospital stay. 
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Fig. 1. Causes of congestive cardiac failure (RHD = rheumatic heart disease; DCM = dilated
cardiomyopathy; HHD = hypertensive heart disease; EMF = endomyocardial fibrosis; IHD =
ischaemic heart disease; Others = 3 patients with degenerative heart disease and 2 with
hypertrophic cardiomyopathy).
Fig. 1. Causes of congestive cardiac failure (absolute numbers) (RHD = 
rheumatic heart disease; DCM = dilated cardiomyopathy; HHD = hyper-
tensive heart disease; EMF = endomyocardial fibrosis; IHD = ischaemic 
heart disease; Others = 3 patients with degenerative heart disease and 2 
with hypertrophic cardiomyopathy).
Table I. Severity and type of anaemia
Haemoglobin (g/dl)
        Frequency             Type of anaemia
               (N)  
Cumulative
                  (N (%))
Haemoglobin (g/dl)    F*       M       %           %   NN            NH              MH
Severe anaemia  (<7.0)    4          5        5.7          5.7   3 (33.3)   4 (44.4)      2 (22.2)
Moderate anaemia (7.0 - 9.9)   25        14      24.8        30.5   33 (84.6)   6 (15.4)      0 (0)
Mild anaemia (10.0 - 11.9)   33        20      33.8        64.3   51 (96.2)   2 (3.8)      0 (0)
Normal (≥12)    42        14      35.7         100   52 (92.9)   4 (7.1)      0 (0)
   Total                   104        53      100     139 (88.5)   16 (10.2)      2 (1.3)
*31 females were menopausal (15 did not have anaemia, 11 had mild anaemia, 4 had moderate anaemia and 1 had severe anaemia). 
NN = normocytic normochromic; NH = normocytic hypochromic; MH = microcytic hypochromic.
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The in-hospital all-cause mortality rate by the end of 2 
weeks of treatment was 10.2%, with the mean number of 
days until death being 4.9 (SD 4.01) days. As expected, the 
greatest mortality occurred among patients with NYHA class 
IV, accounting for 68.2% of the overall mortality. Furthermore, 
19.1% and 5.3% of patients in NYHA classes IV and III 
respectively died during the study period. 
Looking at the causation of CCF, the greatest all-cause 
mortality occurred among patients with hypertensive heart 
disease (HHD), of whom 20.0% died (accounting for 50.0% of 
the deaths overall), followed by patients with rheumatic heart 
disease, of whom 11.1% died (31.2% of deaths overall). The 
odds of dying within 2 weeks were about 5 times higher in the 
anaemic group than in their non-anaemic counterparts, and 
this difference was statistically significant (OR 4.9, CI 1.07 - 
 22.35, p<0.01).
There was no significant difference in duration of 
hospitalisation between the anaemic and non-anaemic patients. 
The average length of stay in the ward was 7.5 (SD 3.4) days, 
with higher NYHA class being associated with longer stay; 
NYHA IV patients averaged 8.5 days, NYHA III patients 7.1 
days and NYHA II patients 2.2 days.
Discussion
We found that 64.3% of CCF patients admitted to the Mulago 
national referral hospital medical wards had anaemia, which 
is comparable to studies done elsewhere.7-9 However, most 
of the studies on anaemia in patients with CCF available for 
comparison were conducted in developed countries, and there 
have been few African studies.10-12  
A study in Israel found a 52.4% prevalence of anaemia in 
CCF patients.7 This study was similar to ours with regard 
to methodology and the NYHA classes (IV and III) of study 
participants. Their patients were generally older, however 
(mean age 76 years), and the underlying cause of CCF was 
predominantly ischaemic heart disease (77.1%), in contrast 
to our patients, who had a mean age of 45 years and in 
whom rheumatic heart disease, dilated cardiomyopathy 
and hypertensive heart disease accounted for over 82% of 
underlying causes. Our findings also contrast with those 
of Inglis et al. in South Africa,10 who found the prevalence 
of anaemia in patients with CCF to be 10%. Although the 
underlying causes of CCF in the South African cohort compare 
fairly well with the Ugandan cohort, the South African study 
clearly recruited patients with relatively milder degrees of 
cardiac failure (NYHA class II 42%, class III 33%),  in which 
anaemia is generally less frequent; moreover, the patients were 
first-time attendees at the cardiology unit. The underlying 
mechanisms of anaemia in cardiac failure mean that first-
time attendees may not have a high prevalence of anaemia 
because chronic cytokine release might not have had the critical 
cumulative effect leading to anaemia of chronic disease. 
The overall prevalence of anaemia in CCF patients in a New 
York study was 61.0%,8 a finding similar to ours, as was the 
mean age of their patients (51.5 years). In our study, 72.4% 
of  patients in NYHA class IV had anaemia compared with 
57.4% in NYHA class III, which correlates with prevalences 
of anaemia of 79.1% and 52.6% in NYHA classes IV and III, 
respectively, in a study in Israel.9 This similarity in prevalence 
is surprising given the differences in mean age of the patients 
in the two studies – the patients in Israel were on average 70 
years old. We found that the prevalence of anaemia in CCF 
increased with increasing patient age, as has been observed 
by others.13 This may be due to increasing co-morbidities with 
ageing. 
On analysis of the causes of CCF, there was a statistically 
significant association between anaemia and hypertensive 
heart disease (OR 0.31, CI 0.13 - 0.74, p<0.01) that might reflect 
some underlying relative degree of hypertensive renal disease 
with concomitant relative erythropoietin deficiency in addition 
to the general mechanisms of anaemia causation in CCF.14
While the prevalence of anaemia in our study is comparable 
to rates in the developed countries, the underlying causes of 
CCF are not. This may imply that the anaemia in our patients 
is occurring as an effect of CCF per se rather than an effect 
related to the underlying cause of the CCF. However, we 
might be dealing with some co-morbidities that have still to be 
identified.  
Valvular heart diseases, EMF, dilated cardiomyopathy and 
hypertensive heart disease (probably because blood pressure 
control is poor) remain significant causes of CCF in our 
patients. This compares well with a South African study11 
in which it was found that hypertensive heart disease and 
dilated cardiomyopathy are the major underlying causes of 
CCF, with few cases of ischaemic heart disease. However, we 
seem to have higher numbers of patients with CCF resulting 
from rheumatic heart disease and EMF, a finding attributed by 
some15 to differences in traditional diet, socio-economic status 
and unidentified infections (eosinophilia). Few patients (1.9%) 
had ischaemic heart disease ascribed to coronary artery disease, 
although we did not do coronary artery angiography. Similarly, 
Sliwa12 found only a small number of patients with ischaemic 
heart disease (9%) in their cardiac failure cohort, whereas 
ischaemic heart disease is the predominant underlying cause of 
CCF in developed societies.7,9 With epidemiological change the 
underlying causes of CCF in our setting will certainly continue 
to evolve.
Mechanisms of anaemia in CCF
Several mechanisms (Fig. 2) have been proposed to explain 
the occurrence of anaemia in CCF, and it is probable that 
individual patients have varying combinations of these. CCF 
plays an important role in the causation of anaemia, mainly 
due to the depressant effects of tumour necrosis factor alpha 
(TNFα),16 which is secreted from the damaged myocardium.9 
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The TNFα  interferes with erythropoietin-induced bone 
marrow stimulation, reduces the production of erythropoietin 
in the kidneys and interferes with the release of iron from the 
reticulo-endothelial system, depriving the bone marrow of 
this essential element for the production of Hb.16 Furthermore, 
the renal failure/damage that inevitably accompanies cardiac 
failure decreases erythropoietin production. In our study, 
where 95% of the participants had a structural cardiac disease 
(rheumatic heart disease, dilated cardiomyopathy, hypertensive 
heart disease or EMF, which lead to structural changes in the 
myocardium) as the underlying cause of CCF, this mechanism 
may have contributed significantly to the high prevalence of 
anaemia.
The reduced renal blood flow caused by CCF can lead to 
renal hypoxia, which can activate the renin-angiotensin axis 
and other growth factors, leading to glomerular and medullary 
damage and consequently proteinuria.17,18 In a vicious circle, 
proteinuria can further damage the renal tubules and reduce 
production of erythropoietin.19 Some degree of erythropoietin 
resistance occurs among CCF patients as a result of elevated 
plasma levels of inflammatory cytokines.20
In patients with chronic cardiac diseases, sequestration of 
iron in macrophages (consequent to chronic diseases) makes 
this nutrient unavailable for haematopoiesis. This would have 
applied to a large proportion of our patients and could have 
contributed to the high prevalence of anaemia.21 In addition, 
poor nutritional intake and gastro-intestinal malabsorption, 
which are common among patients with advanced CCF, could 
have played a role.22
On top of the mechanisms suggested above, the anaemia in 
cardiac failure patients may be due to haemodilution, which in 
one study was responsible for 46% of the anaemia.8 However, 
we did not assess patients for haemodilution.   
Anaemia in patients with cardiac disease can also be 
iatrogenic, caused by drugs such as angiotensin-converting 
enzyme inhibitors and aspirin, which are thought to inhibit 
both erythropoietin production in the kidneys and its 
utilisation in the bone marrow and also cause gastro-intestinal 
bleeding.23,24 
It is also important to note that anaemia is endemic in our 
community, with prevalences of 60.1% in children, 30.2% in 
women and 18.1% in men.25  Whether our high prevalence 
of anaemia reflects the generally high prevalence in the 
community requires further investigation. 
Mortality 
The all-cause in-hospital mortality rate in our study was 10.2%. 
This is comparable to mortality rates in other studies. A study 
in California reported an in-hospital mortality rate of 6.9%.6 
Our rate may be slightly higher because our patients tend to 
present late with advanced disease. Furthermore, differences 
in the underlying cause of CCF may be partly responsible for 
differences in mortality rates. We established that the odds 
of dying in the first 2 weeks after admission for CCF patients 
with anaemia are 5 times higher than for CCF patients without 
anaemia. Early detection and appropriate management of 
anaemia in patients with CCF may improve their outcome.  
Hospital stay
The mean length of hospital stay in our study was 7.5 days. 
The study was designed to follow up patients for a maximum 
of 2 weeks in hospital, yet some patients stayed longer than 
this. Our calculated mean duration of hospitalisation was 
therefore probably lower than would have been the case 
had patients been followed up until discharge. Nordyke and 
James found that their CCF patients spent a mean of 7.4 days 
in hospital, those with anaemia staying longer (p<0.01).6 In a 
Spanish study by Formiga, on the other hand, the mean length 
of stay for patients admitted with new-onset cardiac failure 
was 10 days. 26 We suggest that this longer stay may in part be 
due to the time-consuming diagnostic work-up and counselling 
necessary for new patients. 
Our findings suggest that if we were to measure the Hb 
concentration on admission of every patient with CCF and 
treat anaemia if present, we could provide better care for these 
patients and reduce in-hospital mortality. 
Limitations
We were unable to follow up all patients until discharge and 
therefore cannot come to accurate conclusions on the effect of 
anaemia on length of hospital stay. However, data obtained 
during the 2-week follow-up are sufficient for us to conclude 
that anaemia in CCF signifies an unfavourable outcome.
Recommendations
A long-term follow-up study in a setting similar to ours is 
recommended. Studies looking at optimal treatment of anaemia 
in CCF urgently need to be carried out in sub-Saharan settings.
Fig. 2. Mechanisms contributing to development of anaemia in cardiac failure (CCF =
congestive cardiac failure; RAAS = renin-angiotensin-aldosterone system; TNF = tumour
necrosis factor alpha).
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Fig. 2. Mechanisms contributing to development of anaemia in cardiac 
failure (CCF = congestive cardiac failure; RAAS = renin-angiotensin-al-
dosterone system; TNFα = tumour necrosis factor alpha).
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